

Supplement Contents

Randomization Process Document

DELTA2 Checklist

CONSORT ACE Checklist

DSMB Charter

Declaration of Helsinki

Clinical Trial Protocol (Amendment 5) EudraCT number 2016-004359-57

Supplemental Figure 1. OS in subgroups defined by geographic region

Supplemental Table 1. Dose modification of nababucasin, nab-paclitaxel, and gemcitabine

Supplemental Table 2. Treatment exposure

Supplemental Table 3. Exploratory analysis of the primary and key secondary endpoints in the biomarker positive subgroup*

Figure 14.2.1.3 Forest Plot of Overall Survival by Subgroup (Intent-to-Treat Population)

Table 14.1.2 Patient Accrual by Site (Intent-to-Treat Population)

Table 14.1.3.1 Patient Disposition - End of Study (Intent-to-Treat Population)

Sample Size Calculation (EAST)

Pub Med Extract – search terms

BBI CanStem 111P Interim Analysis Executive Summary Closed Session 01 July 2019